Switzerland
  • Europe
    • FR
    • DE
    • IT
    • ES
    • BE
    • NL
    • LU
    • DK
    • PL
    • UK
  • Switzerland
    • Basel
    • Bern
    • Geneva
    • Lausanne
    • Zürich
  • Schweiz
  • Suisse
  • Alps
  • Business
    • ABB
    • Chubb
    • Glencore
    • Nestlé
    • Novartis
    • Roche
    • UBS
    • Vitol
    • Zurich Insurance
  • NATO
  • US
  • UK
  • Africa
  • Afrique
  • CH

Categories

  • ABB
  • Alps
  • Basel
  • Bern
  • Chubb
  • Geneva
  • Glencore
  • Lausanne
  • Nestlé
  • Novartis
  • Roche
  • Switzerland
  • UBS
  • Vitol
  • Zürich
  • Zurich Insurance
Switzerland
  • Europe
    • FR
    • DE
    • IT
    • ES
    • BE
    • NL
    • LU
    • DK
    • PL
    • UK
  • Switzerland
    • Basel
    • Bern
    • Geneva
    • Lausanne
    • Zürich
  • Schweiz
  • Suisse
  • Alps
  • Business
    • ABB
    • Chubb
    • Glencore
    • Nestlé
    • Novartis
    • Roche
    • UBS
    • Vitol
    • Zurich Insurance
  • NATO
  • US
  • UK
  • Africa
  • Afrique
  • CH

Browsing Tag

neurology

16 posts
RRoche
Roche announces global collaboration with Nurix Therapeutics to co-develop and co-commercialise potential best-in-class BTK degrader bexobrutideg across malignant haematology, immunology and neurology
Read More

Roche announces global collaboration with Nurix Therapeutics to co-develop and co-commercialise potential best-in-class BTK degrader bexobrutideg across malignant haematology, immunology and neurology

  • 2026-06-13
F. Hoffmann-La Roche Ltd Agreement offers potential best-in-class targeted protein degrader therapy option for people living with B-cell…
RRoche
Roche announces global collaboration with Nurix Therapeutics to co-develop and co-commercialise potential best-in-class BTK degrader bexobrutideg across malignant haematology, immunology and neurology
Read More

Roche announces global collaboration with Nurix Therapeutics to co-develop and co-commercialise potential best-in-class BTK degrader bexobrutideg across malignant haematology, immunology and neurology

  • 2026-06-11
F. Hoffmann-La Roche Ltd Agreement offers potential best-in-class targeted protein degrader therapy option for people living with B-cell…
RRoche
Nurix, Roche ink bexobrutideg BTK deal up to $2.3B
Read More

Nurix, Roche ink bexobrutideg BTK deal up to $2.3B

  • 2026-06-08
Nurix Therapeutics (Nasdaq: NRIX) announced a global collaboration with Roche to co-develop and…
RRoche
Roche, Nurix in $2.3B BTK degrader alliance
Read More

Roche, Nurix in $2.3B BTK degrader alliance

  • 2026-06-08
Roche (OTCQX:RHHBY) entered an exclusive global licensing and collaboration agreement with Nurix Therapeutics…
RRoche
Roche announces global collaboration with Nurix Therapeutics to co-develop and co-commercialise potential best-in-class BTK degrader bexobrutideg across malignant haematology, immunology and neurology
Read More

Roche announces global collaboration with Nurix Therapeutics to co-develop and co-commercialise potential best-in-class BTK degrader bexobrutideg across malignant haematology, immunology and neurology

  • 2026-06-08
Agreement offers potential best-in-class targeted protein degrader therapy option for people living with B-cell malignanciesCollaboration adds to Roche’s…
RRoche
Roche announces global collaboration with Nurix Therapeutics to co-develop and co-commercialise potential best-in-class BTK degrader bexobrutideg across malignant haematology, immunology and neurology
Read More

Roche announces global collaboration with Nurix Therapeutics to co-develop and co-commercialise potential best-in-class BTK degrader bexobrutideg across malignant haematology, immunology and neurology

  • 2026-06-08
F. Hoffmann-La Roche Ltd Agreement offers potential best-in-class targeted protein degrader therapy option for people living with B-cell…
BBern
Urs Fischer becomes new ESO president
Read More

Urs Fischer becomes new ESO president

  • 2026-05-15
Urs Fischer Urs Fischer (Inselspital Bern, Bern, Switzerland) has taken over the presidency of the European Stroke Organisation…
RRoche
Roche Receives CE Mark for Alzheimer’s Disease Blood Test
Read More

Roche Receives CE Mark for Alzheimer’s Disease Blood Test

  • 2026-05-13
Roche received the CE mark for its Elecsys pTau217 blood test, an assay designed to detect Alzheimer’s disease…
AAlps
Evaluation of cerebral blood flow and glymphatic function in acute mountain sickness by MRI ASL and DTI ALPS
Read More

Evaluation of cerebral blood flow and glymphatic function in acute mountain sickness by MRI ASL and DTI ALPS

  • 2026-05-04
This prospective study was approved by the Medical Ethics Committee of the Affiliated Hospital of Qinghai University, and…
RRoche
Genentech persevERA breast cancer trial misses PFS goal
Read More

Roche ENSPRYNG cuts MOGAD relapse risk 68%

  • 2026-04-21
Roche (OTCQX: RHHBY) reported Phase III METEOROID results showing ENSPRYNG (satralizumab) reduced risk…
RRoche
Roche Receives CE Mark for Multiple Sclerosis Blood Test
Read More

Roche Receives CE Mark for Multiple Sclerosis Blood Test

  • 2026-04-13
Roche has received the CE mark for its Elecsys Neurofilament Light Chain (NfL) for the detection of neuroinflammation…
AAlps
Association of reduced DTI-ALPS index and increased free water with glymphatic system alterations in noise-induced hearing loss: a neuroimaging study
Read More

Association of reduced DTI-ALPS index and increased free water with glymphatic system alterations in noise-induced hearing loss: a neuroimaging study

  • 2026-04-01
Subjects According to the national standard of the People’s Republic of China, GBZ 49-2014 “Diagnosis of Occupational Noise…
Switzerland
www.europesays.com